Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | JAK1 | P23458 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | ITK | Q08881 | 3/20 | 0.59 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5803139 | 0.97 | AURKA (0.57) | AURKAJAK2JAK1FLT3ITK | |
| SCHEMBL5373352 | 0.91 | LRRK2 (0.62) | JAK2JAK1FLT3ITKLRRK2 | |
| SCHEMBL8251866 | 0.89 | JAK2 (0.74) | AURKAJAK2JAK1ITKLRRK2 | |
| SCHEMBL5383076 | 0.89 | ITK (0.60) | FLT3ITKLRRK2MAP2K4 | |
| SCHEMBL5372220 | 0.89 | MAP2K4 (0.65) | JAK2JAK1FLT3ITKLRRK2 | |
| SCHEMBL14514347 | 0.88 | ITK (0.67) | AURKAJAK2JAK1ITKLRRK2 | |
| SCHEMBL5379148 | 0.88 | JAK2 (0.65) | AURKAJAK2JAK1ITKLRRK2 | |
| SCHEMBL8260093 | 0.86 | JAK2 (0.70) | AURKAJAK2JAK1ITKLRRK2 | |
| SCHEMBL5381989 | 0.84 | AURKA (0.60) | AURKAJAK2JAK1ITKLRRK2 | |
| SCHEMBL5374809 | 0.82 | MAP2K4 (0.65) | JAK2JAK1FLT3LRRK2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| WO-2004094388-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1313711-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | AURKA 3307/4885JAK2 123/4885JAK1 157/4885 |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | AURKA 1001/4885JAK2 296/4885JAK1 365/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | AURKA 1001/4885JAK2 296/4885JAK1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.